President Trump recently announced agreements with Eli Lilly and Company and Novo Nordisk to reduce prices for Ozempic and Wegovy and Zepbound and the Lilly still-in-trials oral GLP-1 orforglipron when purchased through TrumpRx (note this is for cash-paying customers). These reductions in price will enable Medicare and Medicaid coverage of obesity drugs. The Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245. State Medicaid programs will also have access to these medications at these prices. Medicare will cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time, with Medicare beneficiaries paying a copay of just $50 per month. Other Lilly and Novo Nordisk products will have decreased prices offered on TrumpRx, including Emgality, Trulicity, and NovoLog and Tresiba. The agreement also provides that Lilly and Novo Nordisk will provide every state Medicaid program in the country access to Most Favored Nation (MFN) drug prices on their products.
Now how will this impact patient access to these medications via community pharmacies? NCPA is working with the administration to ensure that any GLP-1s covered by Medicare and Medicaid will be available in community pharmacies and that pharmacies will be reimbursed fairly for dispensing these drugs. This will likely occur through a pilot program that is still in the works. Also, we are speaking with the administration about how TrumpRx will work, either as a clearinghouse for current manufacturer direct-to-consumer programs or as a mechanism to access these lower negotiated MFN prices for cash-paying customers. It may ultimately be both. This is all in the works for a likely kickoff date of May 2026 for Medicaid and January 2027 for Medicare. TrumpRx is still being developed and will likely not be ready for primetime until some point in 2026.
Stay tuned, and remember that with so many changes and moving pieces comes opportunity. Here is a fact sheet from the White House with additional information.
